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always the reason for admission,” this 
rise could represent altered disease 
manifestation, severity, or virulence.
In summary, the previously noted 
rate of growth in CDAD-related hospi-
talizations in US adults appears to have 
slowed somewhat in 2006. The encour-
aging downward trend in CDAD in the 
Northeast requires further exploration. 
Of concern is the increasing propor-
tion of CDAD-related hospitalizations 
coded as the primary reason for admis-
sion because this may signal a change 
in characteristics of the disease. Given 
that the new data represent only 1 year, 
and the difference between the raw 
numbers from 2005 through 2006 did 
not reach statistical signifi cance, these 
fi ndings need to be interpreted with 
caution and monitored annually. In gen-
eral, although helpful, most nationwide 
data have a considerable lag time. In 
this and other resistant diseases sweep-
ing the US hospitals, real-time surveil-
lance data are needed for more prompt 
and actionable policy development.
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Pulmonary 
Tuberculosis and 
Mycobacterium 
bovis, Uganda
To the Editor: In 2005, preva-
lence of human tuberculosis (TB) 
in Uganda was 559 cases/100,000 
population (1). In 2002, the average 
number of extrapulmonary TB cases 
in humans, considered a crude indi-
cator of the level of bovine TB, was 
7.5% of TB cases for Uganda and 6% 
for Mbarara district, the main Ugan-
dan milk basin (2). Worldwide, the 
proportion of human cases caused by 
Mycobacterium bovis has accounted 
for 3.1% of all forms of TB (3). Al-
though zoonotic TB is more often re-
ported as an extrapulmonary disease, 
recent publications report that 0.4%–
10% of sputum isolates from patients 
in African countries are M. bovis (3). 
These studies, however, give little 
information about the cattle environ-
ment. A 2002 survey of dairy cattle in 
Mbarara district reported that 74% of 
herds and 6% of individual animals 
were reactive to the single tuberculin 
test (4). However, this test does not 
differentiate between Mycobacterium 
species involved. We therefore ex-
plored whether M. bovis might be a 
major threat to human health in this 
region.
From September 2004 through 
January 2005, we surveyed 658 pa-
tients who had been admitted to the 
Mbarara University Teaching Hospital 
TB ward after positive bacterial fi nd-
ings for at least 3 sputum smears or 
positive chest radiographs for smear-
negative patients. Of 90 randomly se-
lected patients, only 70 samples were 
available for analysis to differentiate 
the species in the M. tuberculosis com-
plex; the other samples were excluded 
because of contamination, lack of my-
cobacteria growth on culture, or postal 
delay in transportation of sample. The 
questionnaire asked about patients’ 
demographic data (including occupa-
tion), association with cattle, and milk 
consumption habits. Genomic DNA 
was extracted from the pellet culture 
of Middlebrook 7H9 broth (Difco; 
Cergy, France) as described previ-
ously (5). DNA samples were used to 
carry out PCRs and hybridization pro-
cesses; we used the GenoType MTBC 
kit (Hain Lifescience GmbH; Nehren, 
Germany) for differentiation in the M. 
tuberculosis complex, especially be-
tween M. tuberculosis and M. bovis 
species (6).
Questionnaire responses showed 
that 27/64 (42.2%; 6 did not answer) 
patients had a history of raw milk con-
sumption; nevertheless, 20/24 (83%; 
3 did not answer) reported that they 
boiled fresh milk before consuming it, 
as did 54/60 (90% of all patients; 10 
did not answer). Eating undercooked 
or raw meat was reported by 91% of 
the patients. Most patients were adult 
males (ratio 2.14:0.97 male:female for 
the district population); 8.6% were <18 
years old (56% in the district); and av-
erage number of persons in household 
was 5.7 vs. 4.8 for the district (7). Of 
the samples, 8.6% were from extrapul-
monary sites.
After amplifi cation and hybrid-
ization of sample DNA, 69 samples 
were found to be M. tuberculosis, and 
1 was not a Mycobacterium species. 
Our sampling method would detect at 
least 1 case of M. bovis in n patient 
specimens if the prevalence of bovine 
TB was > p(0.033%) according to the 
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formula in which a is the fi rst order 
error (5%):
( )p
an −= 1log
log
Because of the change in sample size, 
the limit prevalence was redetermined 
by using the inverse of the formula 
above:
n ap −=1  
If at least 1 sample was positive for 
M. bovis, the prevalence of bovine 
TB among patients would be >4.2%. 
However, the prevalence of M. bovis 
was <4.2% and confi rmed the low-
level involvement of M. bovis in hu-
man TB in Mbarara district. These 
fi ndings are consistent with previous 
work in Uganda’s capital, Kampala, 
and in other African or Asian coun-
tries (2,8,9). The estimation of extra-
pulmonary cases among all TB cases 
(95% confi dence interval 2%–15.2%) 
did not differ from the offi cial esti-
mate. We can add, using the second 
formula shown above, that among 
the 6 extrapulmonary TB cases, the 
prevalence of M. bovis is <39.3%. 
Our results come from a population 
in a highly rural area (91.5% of the 
population in Mbarara district) (7), 
where the high prevalence of animal 
TB has been reported.
These results could be explained 
by the patients’ consumption habits, 
which reduce the risk for contamina-
tion. Even if bovine TB could also be 
found in other farm or wild animals, 
it seems to have a minor effect on 
public health. Zoonotic TB appeared 
to not be a major public health prob-
lem in Mbarara district. However, 
this fi nding could also result from un-
derdiagnosis of extrapulmonary TB, 
from prevalence of M. tuberculosis 
being so high that in proportion M. 
bovis is a minor problem, or from ru-
ral populations’ diffi cult access to TB 
diagnosis (directly observed therapy 
case detection rate in Uganda in 2005 
was 37%) (1).
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Vertical 
Transmission of 
Pneumocystis 
jirovecii in Humans 
To the Editor: Currently, animal 
and human studies favor an airborne 
transmission pattern for Pneumocystis 
pneumonia (1). However, the early 
age of acquisition of Pneumocystis 
spp. in different mammals, including 
humans, warrants study of vertical/
transplacental transmission as an ad-
ditional route of transmission of this 
stenoxenic microorganism.
Available studies on transplacen-
tal transmission of Pneumocystis spp. 
suggest that it varies among mammal 
species on the basis of the type of 
placenta (2). Transplacental transmis-
sion of Pneumocystis spp. has been 
demonstrated in rabbits (2,3), but it 
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